Clinical Trial Application Canada: What to Expect From Health Canada's CTA Review

The 30-day clock starts ticking the moment Health Canada screens your Clinical Trial Application as administratively complete. Not when you submit it. Not when it arrives in their intake system. When they decide it meets the baseline threshold for review — and if they find gaps in that first pass, the clock doesn’t start at all.

For sponsors new to the Canadian regulatory environment, that distinction matters enormously. Many organizations arrive at the CTA process assuming it mirrors the FDA’s 30-day IND review, file accordingly, and then spend the next two months untangling the consequences of a misaligned package. The two systems share philosophical DNA but differ in enough structural ways that a direct transplant of your US submission rarely works.

What a Clinical Trial Application Actually Covers

Under Division 5 of Canada’s Food and Drug Regulations (sections C.05.005 through C.05.012), any sponsor wishing to conduct a clinical trial with an investigational drug must file a CTA with Health Canada before dosing a single participant. The CTA covers three core areas:

• Investigational product quality: manufacturing, characterization, and GMP compliance for the investigational medicinal product (IMP)
• Preclinical safety: non-clinical toxicology and pharmacology data appropriate to the trial’s phase and proposed exposure duration
• Clinical protocol: design, objectives, endpoints, inclusion/exclusion criteria, and the safety monitoring plan

This is not a unified IND package like the US equivalent. Canadian CTAs follow a more modular, CTD-aligned structure closer to European practice — and sponsors who try to repurpose an FDA IND submission without adaptation frequently hit screening objections within the first two weeks. The document you’ll work from is Health Canada’s Guidance Document: Clinical Trial Applications (CTAs) and Amendments, but the format you’ll actually submit follows Module 2.3 (Quality Overall Summary), Module 3 (Quality), and the appropriate non-clinical and clinical sections of the Common Technical Document.

One nuance that catches experienced US teams off guard: the CTA is authorized per protocol, not per drug substance. If your adaptive trial design generates a substantive protocol change mid-study, that triggers an amendment submission — not just a safety update, but a formal regulatory filing with its own review clock.

The 30-Day Review Window: What’s Actually Happening Inside Health Canada

Health Canada’s default scientific review period for a new CTA is 30 calendar days from the date of screening acceptance. For most Phase I trials, this is the operative timeline. Biologics and advanced therapy medicinal products may occasionally warrant a longer review, but 30 days is the standard for small molecules at Phase I.

Here’s what the review actually looks like on their end:

Days 1–5 (Administrative Screening): Health Canada checks for mandatory forms, the HC Submission Cover Page, a Protocol Synopsis, an IMP attestation, a Research Ethics Board letter of intent, correct fees, and format compliance. A deficient submission is returned to the sponsor — the 30-day clock resets entirely, not pauses.

Days 5–25 (Scientific Review): Reviewers from the Therapeutic Products Directorate (TPD) assess the IMP quality dossier and non-clinical data package. For biologics, monoclonal antibodies, and gene therapies, the review goes to the Biologics and Genetic Therapies Directorate (BGTD) — a routing mistake that adds weeks if caught late. Reviewers are asking a single core question: is the proposed human exposure justified by what’s known about this compound?

Days 25–30 (Decision): Health Canada issues either a No Objection Letter (NOL) or a Clinical Hold — a written statement identifying specific deficiencies. Sponsors have 90 days to respond to a Clinical Hold, and the review clock resets once the response is filed.

Getting through all three phases cleanly on the first submission is the goal. But in our experience supporting early-phase biotech and pharmaceutical sponsors, a first-cycle clean NOL happens less often than companies anticipate — particularly for organizations without prior Canadian submission history.

Why CTAs Get Held: The Five Patterns We See Most Often

A Clinical Hold isn’t automatically a catastrophe, but it will cost you 6–8 weeks minimum in a best-case response cycle. The issues that trigger them are, in most cases, avoidable.

1. GMP attestations that don’t match the study batches

If your IMP is manufactured outside Canada — the case for most early-stage biotech sponsors filing a first-in-human trial — you need a GMP attestation confirming the manufacturing site meets standards equivalent to Health Canada’s Division 2 GMP. Health Canada accepts attestations from recognized authorities (FDA, EMA, TGA, and others on the Mutual Recognition Agreement list), but the attestation must be specific to the batch or batches proposed for the trial, not generic site-level certification. Submitting a facility certificate instead of a batch-specific attestation is one of the most common first-submission errors we see.

2. Inadequate dose-escalation justification for Phase I protocols

Health Canada expects the protocol to include a data-supported rationale for the starting dose, the escalation scheme, and the criteria for dose-limiting toxicities. Generic language — “doses will be escalated based on safety committee review” — without explicit stopping rules is a red flag. If your non-clinical package is lean, as it often is in a first-in-human filing, reviewers will lean harder on the clinical protocol for evidence that risk has been thought through carefully.

3. Discrepancies between Module 2.3 and Module 3

The Quality Overall Summary is supposed to be a concise narrative of your Module 3 quality data. When they don’t match — different batch numbers, different specifications, different test method references — reviewers flag it immediately. This sounds like a basic formatting issue, and it is. But it’s surprisingly common in packages assembled by teams that divide writing across multiple contributors without a dedicated cross-check step at the end.

4. Premature or missing Research Ethics Board documentation

Health Canada requires written confirmation that an REB has agreed to review the trial, submitted concurrent with or prior to the CTA. The NOL and REB approval must both be in hand before the first participant can be enrolled. These are parallel processes, not sequential — sponsors who wait for the NOL before engaging an REB add 6–10 weeks to their activation timeline unnecessarily.

5. Biologics routed to TPD instead of BGTD

This one is purely procedural but can waste weeks. Gene therapies, monoclonal antibodies, recombinant proteins, and cell-based products are reviewed by BGTD, not TPD. Contract research organizations familiar with Canadian submissions route these correctly by default; sponsors working from FDA muscle memory sometimes don’t.

Post-Authorization Obligations: Where Sponsors Underestimate the Workload

Receiving your NOL isn’t the end of your regulatory relationship with Health Canada — it’s the beginning. Once a trial is authorized under Division 5, several ongoing obligations apply.

Protocol amendments: Material changes to the protocol require a formal amendment submission. Health Canada’s review period for most amendments is 15 days, though substantive changes can extend that. Sponsors running adaptive trial designs frequently underestimate how many amendments they’ll file over a study’s lifetime — five to ten is not unusual for a complex Phase II.

Serious adverse drug reaction (SADR) reporting: Unexpected serious adverse reactions must be reported to Health Canada within 7 calendar days for fatal or life-threatening reactions, or 15 calendar days for all other serious unexpected reactions. This aligns with ICH E2A but has specific Canadian formatting requirements, and reports go to Health Canada’s Canada Vigilance Program.

Annual Safety Reports (ASRs): Within 60 days of each anniversary of the CTA authorization date, sponsors must file an ASR summarizing the safety profile to date. This catches multi-site Canadian operators off guard when they’re used to the FDA’s annual IND report cycle, which uses a different trigger date and has a different format.

Final Report: Within 6 months of trial completion, discontinuation, or abandonment, a final trial report is required under the regulations. This is a hard legislative deadline.

Planning Your Timeline Realistically

Sponsors targeting a first Canadian trial site often ask what the end-to-end timeline actually looks like. Here’s an honest estimate, assuming no Clinical Hold:

• 6–8 weeks: IMP quality module assembly, protocol finalization, ethics board engagement initiation, non-clinical data review
• 2 weeks: CTA package preparation, QC and cross-module reconciliation, fee calculation and submission
• 1–2 weeks: Health Canada screening review (during which REB engagement continues in parallel)
• 30 calendar days: Scientific review period
• 2–4 weeks: NOL received → site contracts finalized, pharmacy setup, investigator training, drug shipment cleared

That’s 3–5 months from decision-to-file to site activation, assuming a clean first submission. Build in a contingency of 6–8 additional weeks for a one-round Clinical Hold response. For organizations coordinating simultaneous submissions to FDA, EMA, and Health Canada, the Canadian timeline is often the tightest of the three once you account for the administrative screening step that precedes the scientific review.

Working with a Canadian contract research organization that has a dedicated regulatory affairs function reduces Clinical Hold risk substantially — not because CROs have privileged access to reviewers, but because teams with prior Canadian submission history know exactly how Health Canada’s review staff reads module formatting, dose-justification language, and labelling content. They write to that standard from the first draft, which is where first-cycle NOLs are won or lost.

Canada remains one of the most strategically valuable jurisdictions for early-phase clinical research: experienced investigators, a deep network of university-affiliated trial sites, and Health Canada reviewers who are constructive rather than adversarial. Getting your CTA right the first time is what unlocks that value — and it starts well before submission day.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance — Contact us

Related from our network

• GMP testing for investigational drug products and US pharmaceutical submissions — Qalitex Laboratories provides ISO 17025-accredited testing support for sponsors navigating US and cross-border regulatory requirements.
• EU Clinical Trial Regulation and pharmaceutical market entry in Europe — Care Europe covers the regulatory landscape for sponsors expanding into EU markets under the CTR and EMA guidelines.